1

Outstanding Patient Outcomes

BIOTRONIK's newest generation DES: Orsiro Mission - the next level of deliverability for the oustanding Orsiro DES1​​​​​​​. 
Explore Orsiro's extensive clinical program with more than 55,000 patients enrolled2.

BIOFLOW-V

BIOFLOW-V (n = 1,334) the FDA pivotal trial.3,4,5,6,7
Improving patient outcomes, year after year*

Orsiro's extensive clinical program

including BIOFLOW-V

1
Orsiro's extensive clinical program

including BIOFLOW-V

40%

lower TLF rate6 ф

[p=0.003]

46%

lower TV - MI rate6 ф

[p=0.004]

52%

lower Iscemia-driven TLR rate6 ф

[p=0.008]

TLF – Target Lesion Failure; TV-MI – Target Vessel Myocardial Infarction; TLR – Target Lesion Revascularization.
*Compared to Xience, based on three consecutive years. ¤p-values for 36-m frequentist analysis. ф vs. Xience, based on 36-m frequentist analysis.

BIOSTEMI

BIOSTEMI (n=1,300) is the first RCT demonstrating superiority between two contemporary DES8

Principal Investigators of the BIOSTEMI Trial discuss their findings.

Juan F. Iglesias, MD, Geneva, Switzerland, and Thomas Pilgrim, MD, Bern, Switzerland,

“With Orsiro, we incrementally improve care for STEMI patients
Dr. Juan F. Iglesias, Geneva Switzerland Co-Principal Investigator BIOSTEMI trial

*BIOTRONIK data on file, in comparison to Xience based on the Rate Ratio of 0.59.◊Based on author’s interpretation of the BIOSTEMI results

Principal Investigators of the BIOSTEMI Trial discuss their findings.

Juan F. Iglesias, MD, Geneva, Switzerland, and Thomas Pilgrim, MD, Bern, Switzerland,

BIO-RESORT

Small Vessels. Ultrathin Struts. Big Difference9

Orsiro's extensive clinical program

including BIO-RESORT

Orsiro's extensive clinical program

including BIO-RESORT

1. In comparison to Xience Sierra, Resolute Onyx and Synergy for bench tests on pushability, trackability and crossability, BIOTRONIK data on file; 2. BIOTRONIK data on file, status January 2020; 3. Kandzari D et al. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet. 2017 Oct 21; 390(10105):1843-1852; 4. Kandzari D, et al. BIOFLOW-V: A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions Science. Presentation at ESC 2017; 5. Kandzari D et al. Ultrathin bioresorbable polymer sirolimus-eluting stents versus thin durable polymer everolimus-eluting stents. Journal of the American College of Cardiology. 2018 Dec 17;72(25):3287-97; 6. Kandzari D et al. J Am Coll Cardiol. Cardiovasc Interven. 2020, doi: 10.1016/j. jcin.2020.02.019; 7. Kandzari D et al. J Am Coll Cardiol. Cardiovasc Interven. 2020 Supplemental Material; 8. Iglesias JF et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial; Lancet, September, 2019; 9. Buiten R et al. Outcomes in patients treated with thin-strut, very thin-strut, or ultrathin-strut drug-eluting stents in small coronary vessels - A prespecified analysis of the randomized BIO-RESORT trial; JAMA Cardiol. Published online May 21, 2019. doi:10.1001/jamacardio.2019.1776; ClinicalTrials.gov: NCT01674803. 

 

Resolute, Resolute Onyx and Integrity are trademarks or registered trademarks of the Medtronic Group of Companies. Xience and Xience Sierra are trademarks or registered trademarks of the Abbott Group of Companies.

Orsiro and Orsiro Mission are trademarks or registered trademarks of the BIOTRONIK Group of Companies.

Disclaimer
Clinical data conducted with Orsiro, Orsiro Mission’s predecessor device can be used to illustrate Orsiro Mission clinical outcomes.

Orsiro Mission is currently not available in the US.


© 2020 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.